Celyad Oncology SA
F:1C0
Balance Sheet
Balance Sheet Decomposition
Celyad Oncology SA
Celyad Oncology SA
Balance Sheet
Celyad Oncology SA
| Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Cash & Cash Equivalents |
4
|
2
|
2
|
19
|
28
|
100
|
48
|
23
|
41
|
39
|
17
|
30
|
12
|
7
|
4
|
|
| Cash |
4
|
2
|
2
|
0
|
28
|
100
|
48
|
23
|
41
|
39
|
17
|
30
|
12
|
7
|
4
|
|
| Cash Equivalents |
0
|
0
|
0
|
19
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
1
|
0
|
3
|
3
|
7
|
34
|
11
|
9
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
2
|
1
|
0
|
0
|
2
|
1
|
2
|
2
|
1
|
3
|
1
|
2
|
1
|
3
|
1
|
|
| Accounts Receivables |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
1
|
0
|
0
|
2
|
1
|
2
|
2
|
1
|
3
|
1
|
2
|
0
|
2
|
1
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
1
|
1
|
1
|
|
| Total Current Assets |
7
|
4
|
2
|
23
|
33
|
109
|
85
|
36
|
52
|
43
|
20
|
34
|
15
|
11
|
7
|
|
| PP&E Net |
1
|
0
|
0
|
0
|
1
|
1
|
4
|
3
|
3
|
5
|
4
|
3
|
0
|
2
|
1
|
|
| PP&E Gross |
1
|
0
|
0
|
0
|
1
|
1
|
4
|
3
|
3
|
5
|
4
|
3
|
0
|
2
|
1
|
|
| Accumulated Depreciation |
1
|
1
|
2
|
2
|
2
|
2
|
4
|
5
|
5
|
6
|
7
|
8
|
1
|
1
|
1
|
|
| Intangible Assets |
10
|
10
|
10
|
9
|
10
|
48
|
49
|
36
|
35
|
35
|
35
|
35
|
1
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
5
|
6
|
6
|
3
|
3
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Total Assets |
18
N/A
|
14
-21%
|
13
-9%
|
32
+159%
|
44
+36%
|
160
+263%
|
139
-13%
|
78
-44%
|
94
+21%
|
90
-5%
|
66
-26%
|
80
+21%
|
20
-75%
|
16
-17%
|
10
-39%
|
|
| Liabilities | ||||||||||||||||
| Accounts Payable |
1
|
1
|
2
|
2
|
4
|
9
|
8
|
5
|
6
|
7
|
5
|
7
|
5
|
1
|
1
|
|
| Accrued Liabilities |
0
|
1
|
1
|
1
|
1
|
2
|
2
|
1
|
2
|
2
|
2
|
2
|
1
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
4
|
4
|
4
|
1
|
1
|
|
| Total Current Liabilities |
2
|
2
|
4
|
3
|
6
|
11
|
11
|
8
|
10
|
12
|
12
|
14
|
10
|
3
|
3
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
3
|
2
|
0
|
1
|
1
|
|
| Other Liabilities |
6
|
8
|
11
|
12
|
11
|
36
|
36
|
21
|
28
|
29
|
21
|
21
|
5
|
6
|
6
|
|
| Total Liabilities |
9
N/A
|
10
+15%
|
15
+46%
|
16
+5%
|
17
+12%
|
48
+178%
|
48
0%
|
30
-37%
|
39
+29%
|
44
+14%
|
35
-21%
|
36
+3%
|
15
-58%
|
10
-35%
|
9
-6%
|
|
| Equity | ||||||||||||||||
| Common Stock |
0
|
0
|
10
|
22
|
25
|
33
|
33
|
34
|
42
|
49
|
49
|
79
|
79
|
33
|
8
|
|
| Retained Earnings |
9
|
0
|
24
|
39
|
51
|
100
|
124
|
180
|
218
|
74
|
92
|
74
|
115
|
62
|
43
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
33
|
53
|
158
|
158
|
170
|
206
|
43
|
43
|
6
|
6
|
0
|
0
|
|
| Other Equity |
0
|
4
|
11
|
0
|
0
|
21
|
24
|
23
|
26
|
28
|
31
|
33
|
35
|
36
|
36
|
|
| Total Equity |
9
N/A
|
4
-57%
|
2
N/A
|
17
N/A
|
27
+58%
|
111
+318%
|
91
-18%
|
48
-48%
|
56
+17%
|
46
-18%
|
31
-32%
|
44
+41%
|
4
-90%
|
6
+46%
|
1
-92%
|
|
| Total Liabilities & Equity |
18
N/A
|
14
-21%
|
13
-9%
|
32
+159%
|
44
+36%
|
160
+263%
|
139
-13%
|
78
-44%
|
94
+21%
|
90
-5%
|
66
-26%
|
80
+21%
|
20
-75%
|
16
-17%
|
10
-39%
|
|
| Shares Outstanding | ||||||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
6
|
7
|
9
|
9
|
10
|
12
|
14
|
14
|
23
|
23
|
41
|
41
|
|